Collaboration on Development of an mRNA Vaccine between Etana and a Chinese Health Company

PT Etana Biotechnologies Indonesia (Etana) entered into a collaboration agreement with Chinese Health Companies, Walvax and RNA Cure, for the development of an mRNA vaccine, and Cansino for the development of an inhalable tuberculosis vaccine. This Collaboration Agreement was signed by Nathan Tirtana, President Director of Etana together with Management Representatives from three Chinese Health Companies, (27/07).

The signing of this collaboration is a form of Etana's commitment in producing biological drugs and vaccines which are very important and necessary to improve health standards in Indonesia. Etana will be poducing biological medicines and vaccines locally as an effort to support the Government in creating national independence and resilience in the health sector.

The signing of this Cooperation Agreement was carried out in a series of Indonesia-China Healthcare & Biotech Investment Forum events attended by the Indonesian Minister of Health, Budi Gunadi Sadikin; Arsjad Rasjid, General Chair of KADIN; Djauhari Oratmangun, Indonesian Ambassador to the People's Republic of China.

Etana became the first pharmaceutical company in ASEAN to have mRNA technology. MRNA technology is a flexible vaccine development platform so that it can respond quickly to the need for innovative and flexible biopharmaceutical products for cancer, vaccines, and others. It takes a fairly short time in the development of a new vaccine with mRNA technology, the vaccine product is developed and ready to enter the Clinical Trial Phase at approximately two months.